J
Janet Andersen
Researcher at Harvard University
Publications - 136
Citations - 10889
Janet Andersen is an academic researcher from Harvard University. The author has contributed to research in topics: Acute promyelocytic leukemia & Myeloid leukemia. The author has an hindex of 51, co-authored 136 publications receiving 10648 citations. Previous affiliations of Janet Andersen include University of Washington & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Martin S. Tallman,Janet Andersen,Charles A. Schiffer,Frederick R. Appelbaum,James H. Feusner,Angela Ogden,Lois E. Shepherd,Cheryl L. Willman,Clara D. Bloomfield,Jacob M. Rowe,Peter H. Wiernik +10 more
TL;DR: All-trans-retinoic acid as induction or maintenance treatment improves disease-free and overall survival as compared with chemotherapy alone and should be included in the treatment of acute promyelocytic leukemia.
Journal ArticleDOI
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
Raymond T. Chung,Janet Andersen,Paul A. Volberding,Gregory K. Robbins,Tun Liu,Kenneth E. Sherman,Marion G. Peters,Margaret James Koziel,Atul K. Bhan,Beverly Alston,Dodi Colquhoun,Tom Nevin,George Harb,Charles van der Horst +13 more
TL;DR: The marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates that strategies are needed to improve the outcome in persons infected withHCV genotype 1.
Journal ArticleDOI
Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
Shinichi Kitada,Janet Andersen,Sophie Akar,Juan M. Zapata,Shinichi Takayama,Stanislaw Krajewski,Hong Gang Wang,Xin Zhang,Florencia Bullrich,Carlo M. Croce,Kanti R. Rai,John D. Hines,John C. Reed +12 more
TL;DR: Although larger prospective studies are required before firm conclusions can be reached, these studies show the expression in B-CLLs of multiple apoptosis-regulating proteins and suggest that the relative levels of some of these, such as Mcl-1, may provide information about in vivo responses to chemotherapy.
Journal ArticleDOI
Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Diane V. Havlir,Michelle A. Kendall,Prudence Ive,Johnstone Kumwenda,Susan Swindells,Sarojini S. Qasba,Anne F Luetkemeyer,Evelyn Hogg,James F. Rooney,Xingye Wu,Mina C. Hosseinipour,Umesh G. Lalloo,Valdilea G. Veloso,Fatuma Some,N. Kumarasamy,Nesri Padayatchi,Breno Santos,Stewart E Reid,James Hakim,Lerato Mohapi,Peter Mugyenyi,Jorge Sanchez,Javier R. Lama,Jean W. Pape,Alejandro Sanchez,Aida Asmelash,Evans Moko,Fred Sawe,Janet Andersen,Ian Sanne +29 more
TL;DR: In persons with CD4+ T-cell counts of less than 50 per cubic millimeter, earlier ART was associated with a lower rate of new AIDS-defining illnesses and death, as compared with later ART.
Journal ArticleDOI
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial
Andrew R. Zolopa,Janet Andersen,Lauren Komarow,Ian Sanne,Alejandro Sanchez,Evelyn Hogg,Carol Suckow,William G. Powderly +7 more
TL;DR: Early ART resulted in less AIDS progression/death with no increase in adverse events or loss of virologic response compared to deferred ART, and these results support the early initiation of ART in patients presenting with acute AIDS-related OIs, absent major contraindications.